What is the growth forecast for the market?

The market is expected to grow at a CAGR of 6.2% from 2023 to 2029, driven by increasing demand.

What are the key drivers of the market?

Key drivers include rising healthcare costs and the need for personalized medicine, driving future outlook.

What are the major challenges facing the market?

Challenges include data quality issues and regulatory hurdles, impacting market growth.

Which regions are expected to lead the market?

North America and Europe are expected to be regional leaders, due to high adoption rates.

Who are the top companies in the market?

Top companies include IBM, Optum, and IQVIA, providing innovative solutions.

What future opportunities exist in the market?

Future opportunities include integration with emerging technologies, such as AI and blockchain.

How will technology impact the market?

Technology will enable more efficient data collection and analysis, driving real world evidence in healthcare 2029 market growth.

What is the current regulatory landscape for the market?

The regulatory landscape is evolving, with a focus on data privacy and security, shaping the future outlook.

real world evidence in healthcare 2029 Growth Drivers & Forecast Analysis 2033

real world evidence in healthcare 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $10800 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $10800 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

real world evidence in healthcare 2029 Market Size | CAGR 15.2 Forecast 2033

real world evidence in healthcare 2029 Growth Drivers & Forecast Analysis 2033

real world evidence in healthcare 2029 by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $10800 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $10800 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

real world evidence in healthcare 2029 Market Overview

The real world evidence in healthcare 2029 market refers to the collection and analysis of data from real-world sources, such as electronic health records, claims data, and patient registries, to inform healthcare decisions. As the healthcare industry continues to evolve, the real world evidence in healthcare 2029 market size is estimated to be around $1.8 billion, with a growth outlook that is expected to drive significant expansion in the industry. The market forecast suggests a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033, driven by macro drivers such as the increasing demand for personalized medicine, the need for more effective and efficient clinical trials, and the growing importance of patient-centric care. The scope of the market includes the use of real-world evidence in pharmaceuticals, biotechnology, and medical devices, with applications in clinical trials, market access, and post-marketing surveillance.

Loading chart…

The real world evidence in healthcare 2029 market is shaped by key forces such as technology shifts, regulatory requirements, and changing consumer behavior. The largest region in the market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the increasing adoption of digital health technologies and the growing demand for personalized medicine. The industry is expected to experience significant expansion in the coming years, driven by the increasing use of real-world evidence in clinical decision-making, market access, and post-marketing surveillance.

Report Overview

Report Attribute	Details
Market size value in 2025	10.80 billion
Revenue forecast in 2033	33.50 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	IQVIA; Syneos Health; Optum; ICON plc; Verantos; EVERSANA; Aetion; Phesi; Groupe IMPACT; ConcertAI; PAREXEL International; ZS Associates; Trinity Life Sciences; Cegedim; Appian; Real-World Data Services, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The real world evidence in healthcare 2029 market is poised for significant growth, driven by factors that are reshaping the healthcare landscape. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Increasing demand for personalized medicine and targeted therapies is driving the adoption of real-world evidence (RWE) to support treatment decisions and improve patient outcomes, ultimately influencing the real world evidence in healthcare 2029 market size.

Advancements in data analytics and artificial intelligence are enhancing the collection, analysis, and interpretation of RWE, providing actionable insights that inform healthcare strategies and contribute to the growth forecast of the real world evidence in healthcare 2029 market.

Restraints2 items

Concerns over data privacy and security are significant restraints, as the use of RWE often involves sensitive patient information, necessitating robust safeguards to protect against breaches and maintain trust in the real world evidence in healthcare 2029 market.

The regulatory environment for RWE is still evolving, with varying standards and guidelines across different regions, which can create uncertainty and barriers to entry for companies seeking to operate in the global real world evidence in healthcare 2029 market.

Opportunities2 items

The integration of RWE with emerging technologies such as blockchain and the Internet of Things (IoT) presents opportunities for more efficient, secure, and patient-centric healthcare solutions, potentially expanding the real world evidence in healthcare 2029 market size.

Growing patient engagement and the rise of patient-generated data are opening new avenues for RWE collection and analysis, enabling more inclusive and representative research that can better reflect real-world outcomes and inform growth forecast projections.

Challenges2 items

One of the significant challenges facing the real world evidence in healthcare 2029 market is the standardization of data, as variability in data quality, format, and sources can hinder comparability and reliability, affecting the overall validity of RWE studies.

Addressing health disparities and ensuring that RWE represents diverse patient populations is a critical challenge, requiring concerted efforts to include underrepresented groups in research and analyses to provide a comprehensive view of the real world evidence in healthcare 2029 market.

Market Segmentation

Loading chart…

The real world evidence in healthcare 2029 segmentation is categorized based on application, which includes disease registry, post-marketing surveillance, medical device safety, and pharmacovigilance. Each of these subtypes contributes significantly to the overall market size, providing valuable insights into the healthcare landscape.

The disease registry segment plays a crucial role in the real world evidence in healthcare 2029 market, as it helps track and monitor disease patterns, treatment outcomes, and patient demographics. This information is essential for healthcare stakeholders to develop targeted interventions and improve patient care.

The post-marketing surveillance segment is another vital component of the market, focusing on monitoring the safety and efficacy of pharmaceuticals and medical devices after they have been approved for commercial use. This segment contributes to the overall market size by providing critical insights into the real world evidence in healthcare 2029 segmentation.

The medical device safety segment is a key area of focus, as it ensures the safe use of medical devices in real-world settings. This segment contributes to the market size by identifying potential safety risks and informing strategies to mitigate them, ultimately enhancing patient outcomes.

The pharmacovigilance segment is responsible for monitoring the safety of pharmaceuticals, detecting potential adverse events, and evaluating the risk-benefit profile of drugs. This segment is essential to the real world evidence in healthcare 2029 market, as it enables healthcare stakeholders to make informed decisions about medication use.

Regional Insights

Loading chart…

The real world evidence in healthcare 2029 market growth is expected to be driven by various regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of real-world evidence solutions, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America - established ecosystem maturity, high demand for personalized medicine, and stringent regulatory requirements; Europe - growing demand for real-world evidence, increasing focus on patient outcomes, and rising investments in digital health; Asia Pacific - expanding patient population, increasing healthcare expenditure, and growing adoption of digital health technologies; Latin America - growing demand for healthcare services, increasing focus on preventive care, and rising investments in healthcare infrastructure; Middle East & Africa - growing healthcare expenditure, increasing focus on digital health, and rising adoption of real-world evidence solutions.

The regional forecast indicates that the real world evidence in healthcare 2029 market will experience significant growth, driven by the increasing adoption of real-world evidence solutions, favorable policies, and investments in healthcare infrastructure. The Asia Pacific region is expected to drive the market growth, with a compound annual growth rate of approximately 15%.

Competitive Landscape

The real world evidence in healthcare 2029 competitive landscape is moderately consolidated, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals, with companies focusing on real world evidence in healthcare 2029 key players to gain a competitive edge. The market is characterized by high competition, with companies employing various strategies to differentiate themselves.

Companies in the market employ common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have notable strategies:

IQVIA: regional expansion

Optum: vertical integration

Syneos Health: premium pricing

ICON plc: innovation pipeline

Aetion: local manufacturing

Verantos: OEM tie-ups

Key real world evidence in healthcare 2029 Companies16 items

IQVIA

Syneos Health

Optum

ICON plc

Verantos

EVERSANA

Aetion

Phesi

Groupe IMPACT

ConcertAI

PAREXEL International

ZS Associates

Trinity Life Sciences

Cegedim

Appian

Real-World Data Services, Inc.

Market Ecosystem

The real world evidence in healthcare 2029 ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the generation, analysis, and application of real-world data, which informs healthcare decision-making. This ecosystem is characterized by a complex interplay of participants, each contributing to the development, validation, and utilization of real-world evidence.

Technology providers — develop data analytics platforms

Data/analytics providers — supply real-world data sources

System integrators / EPCs — implement evidence generation systems

Distributors / channel partners — facilitate access to evidence platforms

Service providers / after-sales — offer consulting and support services

End users / buyers — apply real-world evidence in healthcare decision-making

Regulators/standards bodies — establish guidelines and oversight frameworks

The flow of value within the real world evidence in healthcare 2029 ecosystem is influenced by control points, such as regulatory approvals and standards, which can create bottlenecks and impact adoption. Dependency risks, including input constraints and data quality issues, can also affect the ecosystem's functioning. Moreover, switching costs, partnerships, and interoperability requirements can pose challenges for participants. As the ecosystem differs by region, due to varying regulatory frameworks and healthcare systems, participants must navigate these nuances to succeed in the global market, ultimately requiring a thorough understanding of the real world evidence in healthcare 2029 ecosystem.

Recent Industry Insights

The real world evidence in healthcare 2029 industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed between major pharmaceutical companies and technology firms to leverage artificial intelligence and machine learning in generating high-quality real-world evidence. Mergers and acquisitions have also been prominent, with several companies expanding their capabilities in data analytics and healthcare research.

Recent product launches have focused on cloud-based platforms and data management solutions to support the integration and analysis of real-world data. Regulatory changes, such as the increased adoption of real-world evidence by regulatory agencies, have further driven the growth of the market. Additionally, there has been a significant shift in consumer trends towards personalized medicine, and enterprise trends towards more efficient and effective clinical trials.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the real world evidence in healthcare 2029 market outlook. The market attractiveness is driven by the increasing demand for personalized medicine and the need for more accurate treatment outcomes. The competitive intensity is moderate, with key players investing heavily in research and development to stay ahead in the market.

The long-term outlook for the market is optimistic, with the innovation landscape expected to witness significant advancements in artificial intelligence and data analytics. However, the demand-supply balance may be affected by key risk factors such as regulatory challenges and data privacy concerns. Overall, the real world evidence in healthcare 2029 market is poised for growth, driven by the increasing adoption of real-world data and evidence-based medicine.

11 items

1. Executive Summary

2. real world evidence in healthcare 2029 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global real world evidence in healthcare 2029 Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global real world evidence in healthcare 2029 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global real world evidence in healthcare 2029 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global real world evidence in healthcare 2029 Market Competition by Key Manufacturers

8.1. Global real world evidence in healthcare 2029 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global real world evidence in healthcare 2029: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. IQVIA

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Syneos Health

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Optum

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. ICON plc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Verantos

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. EVERSANA

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aetion

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Phesi

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Groupe IMPACT

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. ConcertAI

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. PAREXEL International

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. ZS Associates

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Trinity Life Sciences

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Cegedim

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Appian

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Real-World Data Services, Inc.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global real world evidence in healthcare 2029 Market

Figure 4: Global real world evidence in healthcare 2029 Market: Drivers

Figure 5: Global real world evidence in healthcare 2029 Market: Challenges

Figure 6: Global real world evidence in healthcare 2029 Market: Trends

Figure 7: Global real world evidence in healthcare 2029 Market: Opportunity

Figure 8: Global real world evidence in healthcare 2029 Market: Restraint

Figure 9: Global real world evidence in healthcare 2029 Market: Porter's Five Forces

Figure 10: Global real world evidence in healthcare 2029 Market Value (USD Million) By Region

Figure 11: Global real world evidence in healthcare 2029 Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global real world evidence in healthcare 2029 Market Value (USD Million) By Region

Figure 15: Global real world evidence in healthcare 2029 Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

55 items

Table 1: Market Segmentation Analysis

Table 2: Global real world evidence in healthcare 2029 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global real world evidence in healthcare 2029 Market Value (USD Million) By Region

Table 4: Global real world evidence in healthcare 2029 Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global real world evidence in healthcare 2029 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global real world evidence in healthcare 2029 Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global real world evidence in healthcare 2029 Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: IQVIA Basic Information And Sales Area

Table 15: IQVIA. Products Portfolio

Table 16: Syneos Health Basic Information And Sales Area

Table 17: Syneos Health. Products Portfolio

Table 18: Optum Basic Information And Sales Area

Table 19: Optum. Products Portfolio

Table 20: ICON plc Basic Information And Sales Area

Table 21: ICON plc. Products Portfolio

Table 22: Verantos Basic Information And Sales Area

Table 23: Verantos. Products Portfolio

Table 24: EVERSANA Basic Information And Sales Area

Table 25: EVERSANA. Products Portfolio

Table 26: Aetion Basic Information And Sales Area

Table 27: Aetion. Products Portfolio

Table 28: Phesi Basic Information And Sales Area

Table 29: Phesi. Products Portfolio

Table 30: Groupe IMPACT Basic Information And Sales Area

Table 31: Groupe IMPACT. Products Portfolio

Table 32: ConcertAI Basic Information And Sales Area

Table 33: ConcertAI. Products Portfolio

Table 34: PAREXEL International Basic Information And Sales Area

Table 35: PAREXEL International. Products Portfolio

Table 36: ZS Associates Basic Information And Sales Area

Table 37: ZS Associates. Products Portfolio

Table 38: Trinity Life Sciences Basic Information And Sales Area

Table 39: Trinity Life Sciences. Products Portfolio

Table 40: Cegedim Basic Information And Sales Area

Table 41: Cegedim. Products Portfolio

Table 42: Appian Basic Information And Sales Area

Table 43: Appian. Products Portfolio

Table 44: Real-World Data Services, Inc. Basic Information And Sales Area

Table 45: Real-World Data Services, Inc.. Products Portfolio

Table 46: Global real world evidence in healthcare 2029 Market Value (USD Million) By Region

Table 47: Global real world evidence in healthcare 2029 Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: South America Market Value (USD Million) (2025-2032) By Country

Table 52: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 53: Research Programs/Design For This Report

Table 54: Key Data Information From Secondary Sources

Table 55: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

real world evidence in healthcare 2029 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	10.80 billion
Revenue forecast in 2033	33.50 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	IQVIA; Syneos Health; Optum; ICON plc; Verantos; EVERSANA; Aetion; Phesi; Groupe IMPACT; ConcertAI; PAREXEL International; ZS Associates; Trinity Life Sciences; Cegedim; Appian; Real-World Data Services, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options